Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Small Cell Lung Carcinoma × etirinotecan pegol × Clear all

Phase

Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Small Cell Lung Carcinoma 1

Interventions

Etoposide 15 Carboplatin 14 pembrolizumab 13 Cisplatin 9 Topotecan 7 Nivolumab 7 Irinotecan 7 atezolizumab 6 Paclitaxel 5 PM 01183 5 Ipilimumab 5 Gemcitabine 5 olaparib 4 Temozolomide 4 Radiotherapy 4 surufatinib 3 durvalumab 3 carfilzomib 3 Docetaxel 3 Bevacizumab 3 veliparib 2 trilaciclib 2 sacituzumab govitecan 2 rovalpituzumab tesirine 2 obatoclax 2 navitoclax 2 lenvatinib 2 epacadostat 2 berzosertib 2 Vorinostat 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05158491 2022-01-05

Safety, Tolerability and Preliminary Efficacy of JK1201I in Patients With SCLC

JenKem Technology Co., Ltd.

Phase 1/2 Unknown

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡